National Physicians Alliance Statement on Treatment of Opioid Use Disorder
The National Physicians Alliance supports access to evidence-based treatment for opioid use disorder, including medication-assisted therapies such as methadone, buprenorphine and naltrexone. Only 1 in 10 people with substance use disorders currently receive treatment. We hope that Health and Human Services Secretary Tom Price will continue to promote access to effective treatments including medication-assisted therapy, as a means of improving the lives of people with opioid use disorder. No family should have to cope with the death of loved one from an opioid overdose because of a lack of available treatment.
According to NPA board member Anthony J. Accurso, MD, General Internist and Addictionologist from NYC, “Medication-Assisted Therapies (MAT) for opioid use disorder are evidence-based and proven to retain patients in treatment and reduce the risk of overdose. The increasing presence of fentanyl and carfentil in street-acquired heroin makes the current risk of overdose even greater. People with opioid-use disorder who obtain buprenorphine or methadone are not subject to the uncertainty of the heroin composition, and are therefore safer.”
###
CONTACT:
Becky Martin, Advocacy Director
National Physicians Alliance
c: 941/518-7051
becky@npalliance.org
Barbara Meier schreibt seit vielen Jahren für die NPAlliance Ratgeber und Testberichte. Dabei legt sie großen Wert auf die Ausführlichkeit sowie Richtigkeit ihrer Artikel. Sie zählt zu den wenigen Experten in ihrem Gebiet und hat sich über die letzten Jahren einen Namen in der Gesundheitsbranche gemacht.